Advertisement: Kao Data Centre mid banner
Advertisement: Mogrify mid banner
Advertisement: Excalibur Healthcare mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement: Cambridge Network mid banner
Advertisement: partnersand mid banner
Advertisement: RSM mid banner
Advertisement mid banner S-Tech 1
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement: CJBS mid banner
ARM Innovation Hub
Advertisement: EBCam mid banner
16 October, 2021 - 21:24 By Tony Quested

AstraZeneca unveils great potential of Covid cocktail

An antibody cocktail from Cambridge’s AstraZeneca is set to slash the risk of severe illness and death from Covid.

AZD7442 is now unchallenged globally as the only long-acting antibody combination shown to both prevent and treat COVID-19.

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca’s AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death. That compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.

A total of 90 per cent of participants enrolled were from populations at high risk of progression to severe COVID-19, including those with co-morbidities.

The trial met the primary endpoint, with a dose of 600mg of AZD7442 given by intramuscular injection reducing the risk of developing severe COVID-19 or death (from any cause) by 50 per cent compared to placebo in outpatients who had been symptomatic for seven days or less. 

The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415). The LAAB was generally well tolerated in the trial. AZD7442 is the first LAAB with Phase III data to demonstrate benefit in both prophylaxis and treatment of COVID-19 and is easily administered by IM injection.

Mene Pangalos, executive VP BioPharmaceuticals R & D at AstraZeneca, said: “These important results for AZD7442, our long-acting antibody combination, add to the growing body of evidence for use of this therapy in both prevention and treatment of COVID-19.

“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months.”

AstraZeneca will be discussing the data with health authorities. 

Newsletter Subscription

Stay informed of the latest news and features